-
Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies
Tuesday, September 10, 2024 - 4:40pm | 445Incannex Healthcare Inc. (NASDAQ:IXHL), a cannabinoid and psychedelic medicine biotechnology company, announced Tuesday a significant financing agreement with Arena Investors, securing up to $60 million in funding. The deal includes $10 million in convertible notes and a $50 million equity line of...
-
Fortrea To Manage Incannex's FDA IND Opening Phase 2/3 Trial Of Its Dronabinol-Based Drug For Obstructive Sleep Apnea
Tuesday, July 18, 2023 - 9:03am | 467Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL) has engaged Fortrea (NASDAQ: FTRE) as the contract research organisation for management of the IND opening phase 2/3 clinical trial investigating IHL-42X for treatment of obstructive sleep apnea (OSA). The phase 2/3 clinical trial will assess...
-
Incannex Stock Trading Higher On Entering A Lease For First Psychedelic-Assisted Psychotherapy Clinic
Friday, May 5, 2023 - 8:39am | 359Incannex Healthcare Ltd (NASDAQ: IXHL) (ASX:IHL) announced that its subsidiary company, Clarion Clinics Group Pty Ltd, has entered a lease for riverfront premises in Abbottsford, Melbourne. The premises will be used to provide psychedelic-assisted psychotherapy. Fit out and commissioning of these...
-
Incannex Engages Catalent For Development And Manufacture Of Psilocybin Drug For Clinical Trials
Friday, March 3, 2023 - 10:27am | 543Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, has engaged Catalent (NYSE: CTLT) to develop and manufacture a cGMP-grade psilocybin drug product for: use...
-
Incannex Healthcare To Acquire APIRx Pharmaceuticals For $93.3M
Thursday, March 24, 2022 - 8:36am | 499Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL) announced that it has executed a term sheet with binding commercial terms to wholly acquire APIRx Pharmaceutical USA, LLC, subject to shareholder approval under ASX listing Rule 7.1. The proposed acquisition is for 100% of the issued share...
-
Psychedelics And Virtual Reality Treatment Developed By Monash University, Funded By Incannex
Thursday, March 3, 2022 - 10:46am | 457Incannex Healthcare Limited (Nasdaq: IXHL) (ASX:IHL) has implemented a license agreement with Monash University to develop a novel treatment that combines virtual reality and psychedelics. This marks the initiation of a second clinical psychedelic therapy program. "We're delighted to have...
-
Medicinal Cannabis And Psychedelics Company Incannex Lists American Depositary Shares On Nasdaq
Monday, February 28, 2022 - 12:08pm | 350Medicinal cannabis and psychedelics company Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) commenced trading of its American Depositary Shares representing its ordinary shares on the Nasdaq Global Market under the ticker symbol 'IXHL'. Each IXHL ADS represents 25 ordinary shares of...